Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 3/20 | 0.30 |
| ▸ | SRC | P12931 | 3/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | RAD52 | P43351 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4018383 | 0.82 | KMT2A (0.41) | CYP1A2CYP2C19MEN1KMT2AGABBR2 | |
| SCHEMBL4018380 | 0.82 | KMT2A (0.41) | CYP1A2CYP2C19MEN1KMT2AGABBR2 | |
| SCHEMBL13769292 | 0.79 | ABL1 (0.34) | PDE10AABL1SRC | |
| SCHEMBL27168835 | 0.62 | ALDH1A1 (0.36) | KMT2A | |
| SCHEMBL18484573 | 0.62 | CA1 (0.36) | CYP1A2CYP2C19CYP3A4CYP2D6ABL1 | |
| SCHEMBL10899963 | 0.62 | KMT2A (0.43) | CYP1A2CYP2C19MEN1KMT2AGABBR2 | |
| SCHEMBL11840208 | 0.59 | CYP3A4 (0.45) | CYP1A2CYP2C19CYP3A4CYP2D6ABL1 | |
| SCHEMBL2354445 | 0.59 | CYP1A2 (0.48) | CYP1A2CYP2C19CYP3A4CYP2D6MEN1 | |
| SCHEMBL11834297 | 0.58 | CYP1A2 (0.50) | CYP1A2CYP2C19CYP3A4CYP2D6ABL1 | |
| SCHEMBL21282880 | 0.57 | CA1 (0.46) | CYP1A2CYP2C19CYP3A4CYP2D6PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566708-B2 | Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-28 | — | — | US | disclosed |
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | MAPKAPK2, MAPK1, MAP3K2 | CYP1A2 3826/4885CYP2C19 4750/4885CYP3A4 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.